Document:

Exhibit 10.25

 

FOIA CONFIDENTIAL TREATMENT REQUEST BY

INVENTERGY GLOBAL, INC.

IRS EMPLOYER IDENTIFICATION NUMBER 62-1482176

Confidential treatment requested with
respect to certain portions hereof denoted with

“***”

 

	***CONFIDENTIAL TREATMENT REQUESTED***
	 
	Note: Confidential treatment requested with respect to certain portions hereof denoted with “***”

 

SECOND AMENDMENT TO AMENDED AND RESTATED

REVENUE SHARING AND NOTE PURCHASE AGREEMENT

 

This SECOND AMENDMENT
TO AMENDED AND RESTATED REVENUE SHARING AND NOTE PURCHASE AGREEMENT (this “2nd Amendment”) is dated
as of November 30, 2015 among Inventergy Global, Inc., a Delaware corporation (“Parent”), Inventergy, Inc. (“Owner”,
and, collectively, the “Company”), DBD Credit Funding, LLC as collateral agent (the “Collateral Agent”),
and the Revenue Participants and Note Purchasers (collectively, the “Purchasers”) thereto, and amends that certain
Amended and Restated Revenue Sharing and Note Purchase Agreement between the Company, the Collateral Agent and the Purchasers originally
dated as of October 1, 2014 and amended and restated as of February 25, 2015, and further amended as of October 30, 2015 (such
Agreement, as amended hereby and as may be further amended, supplemented or otherwise modified and in effect from time to time,
the “Agreement”). Capitalized terms used and not otherwise defined in this 2nd Amendment shall have
the meanings specified in the Agreement.

 

WHEREAS, the Company
has requested (i) that amortization payments begin on the last Business Day of January 2016, rather than the last Business Day
of November 2015, (ii) that the Liquidity maintenance requirement of not less than One Million Dollars ($1,000,000) not apply to
the Company from December 1, 2015 to February 1, 2016, (iii) that the Company be permitted to retain for application to certain
fees owed to a consultant being retained by the Company certain Monetization Net Revenues that would otherwise be required to be
applied to the Note Obligations, and (iv) that the Company’s payment obligations to Nokia be permitted on the date due and
not 30 days prior, or otherwise incur interest to Nokia on any amounts then owed, depending on certain conditions.

 

WHEREAS, the Purchasers are prepared to
agree to the Company’s requests, on the terms and conditions set forth herein.

 

NOW THEREFORE, in consideration
of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the parties hereto
hereby agree as follows:

 

Section
1.  Amendments. The Agreement shall be amended as follows:

 

     

     

    

 

1.01.   Amortization.
Section 2.2.4.3 of the Agreement shall be amended to replace the phrase “Commencing on the last Business day of November,
2015” with “Commencing on the last Business day of January, 2016”.

 

1.02.   Patent
License. Section 2.7 shall be amended by replacing the last sentence of such Section with the following: “The Collateral
Agent and the Secured Parties agree that the Collateral Agent shall only use such license (a) following the occurrence and during
the continuance of an Event of Default (including, without limitation, an Event of Default on account of a breach of the minimum
liquidity requirement of Section 6.10 or on account of a payment default arising from a failure to timely make any required amortization
payments); or (b) from December 1, 2015 until the later of (x) February 1, 2016, (y) the Company’s delivery of a compliance
certificate demonstrating compliance with Section 6.10 for any week on or after the week ended February 4, 2016, and (z) the date
on which the Company shall have made the second of two consecutive monthly amortization payments in accordance with Section 2.2.4.3.”

 

1.03.Sale
Waterfall. A new Section 2.9 shall be added as follows:

 

“2.9   Proceeds
of Sale of Patents. Notwithstanding any other provision of this Agreement, in the event of a sale or exclusive license of all
or a portion of the Patents (a “Patent Sale”) the proceeds of any such sale, as and when received by the Company,
shall be applied as follows:

 

i)     100%
of the Patent Sale Net Proceeds from such sale or exclusive license shall be applied to the Note Obligations (which shall include
any principal, interest, termination fees, legal fees or other expenses of the Collateral Agent in connection with such transaction)
until paid in full.

 

ii)    Following
the payment in full of the Note Obligations, 75% of the remaining Patent Sale Net Proceeds shall be applied to the Revenue Stream
until the amount applied to the Revenue Stream pursuant to this clause (ii) totals $5 million.

 

iii)   Following
the application of $5 million to the Revenue Stream pursuant to clause (ii), 50% of the remaining Patent Sale Net Proceeds shall
be applied to the Revenue Stream until the amount applied to the Revenue Stream pursuant to this clause (iii) totals $3,539,650
if paid by the Maturity Date, or $5,369,575 if paid thereafter.

 

     

     

    

 

For purposes
of this Section 2.9, “Patent Sale Net Proceeds” of a Patent Sale, shall mean the total gross Monetization Revenues
of such transaction, less the following (i) any brokers’ commissions that have been approved, in advance, by the Collateral
Agent, (ii) the Company’s reasonable documented legal fees and expenses directly related to such transaction; provided, for
the avoidance of doubt, that no legal fees or expenses incurred prior to December 1, 2015 shall be deducted from such gross proceeds,
less (iii) solely in the case of a Patent Sale of the Panasonic and Huawei Patents, Contractual Obligations of the Company to certain
third parties as detailed below. Specifically, in the case of Panasonic patents, such third party Contractual Obligations consist
of 20% of gross transaction proceeds owed to Panasonic, 2% of “***Net Monetization Revenues” owed to *** (with such
term defined in the agreement between the Company and ***), and 4% of “*** Net Monetization Revenues”, up to a pre-determined
limit, owed to *** (with such term defined in the engagement letter between the Company and ***). In the case of
Huawei patents, such third party Contractual Obligations consist of 20% of “Huawei Net Monetization Revenues” owed
to Huawei (with such term defined in the Patent Purchase Agreement between the Company and Huawei), 10% of gross transaction proceeds,
up to a pre-determined limit, owed to ***, 2% of “*** Net Monetization Revenues” owed to *** (with such term defined
in the agreement between the Company and ***), and 4% of “*** Net Monetization Revenues”, up to a pre-determined limit,
owed to *** (with such term defined in the engagement letter between the Company and ***).

 

By way of
illustration, and this example assumes a transaction takes place prior to the Maturity Date, thereby requiring payment of the lower,
“Pre-Maturity Date” Revenue Stream obligation, assuming (i) that the gross proceeds of a sale of some or all of the
Panasonic Patents totals $50,000,000, (ii) that the broker’s commission is owed pursuant to the *** Brokerage Agreement,
(iii) that the Note Obligations (including expenses of the Collateral Agent) total $10,906,465 as of such date, which consist of
$10,052,500 of principal outstanding and $853,965 of termination fees (PIK interest has been excluded for this example only), (iv)
that the legal fees and disbursements of the Company in connection with such transaction totals $100,000, and (v) that allowable
deductible expenses for purposes of calculating third party Contractual Obligations under the Company’s agreements with third
parties are $2,000,000 in all cases, then the proceeds of such sale shall be distributed as follows:

 

$50,000,000
would generate a commission due to *** under the *** Brokerage Agreement of (0.1 x $1,000,000) + (0.075 x $4,000,000) + (0.05 x
$45,000,000) = $2,650,000.

 

     

     

    

 

Patent Sale
Net Proceeds would be calculated as:

 

	Gross Proceeds	 	$	50,000,000	 
	Less *** fees	 	$	(2,650,000	)
	Less Company legal fees	 	$	(100,000	)

(Note:
Contractual Obligations to *** if this was a Huawei/Nokia sale would be 10% of gross transaction proceeds up to a
total of approx.. $*** based on previously deferred legal billings))

	Less Contractual Obligation to Panasonic	 	$	(10,000,000	)
	Less Contractual Obligation to ***	 	$	(960,000	)
	  (Or to *** if this was a Huawei/Nokia sale)	 	 	 	 
	Less Contractual Obligation to ***	 	$	(336,600	)
	Net Proceeds	 	$	35,953,400	 

 

i)  $10,906,465 is applied
to the Note Obligations, leaving $25,046,935 of Patent Sale Net Proceeds;

 

ii)  Of the next $6,666,667
in Patent Sale Net Proceeds, $5,000,000 is applied to the Revenue Stream and $1,666,667 to the Company, leaving $18,380,268 in
remaining Patent Sale Net Proceeds;

 

iii)  Of the remaining
$18,380,268, $3,539,650 is applied to the Revenue Stream, leaving $14,840,618, which will be paid to the Company.

 

The result of the foregoing distribution
of $50,000,000, after payment of $2,750,000 in transaction expenses, is a total of $19,446,115 being paid to the Purchasers, $16,507,285
being paid to the Company, and $11,296,600 being paid to satisfy third party Contractual Obligations.”

 

1.04.  Management
of Patents; Dispositions. Section 6.9.1 of the Agreement shall be amended by replacing clause (iv) thereof with the following:
“and (iv) prior to December 1, 2015, the entry into contingency, revenue sharing or profit sharing arrangements with additional
law firms, consultants or other professionals to the extent such arrangements are not inconsistent with the Purchasers’ rights
in respect of the Monetization Revenues hereunder.”

 

1.05.  Minimum
Liquidity. The requirement in Section 6.10 of the Agreement that the Company shall maintain not less than One Million Dollars
($1,000,000) in unrestricted cash and Cash Equivalents shall not apply from November 1, 2015 until February 1, 2016.

 

1.06.  Obligations
under Patent Purchase Agreements. Section 6.14(a) of the Agreement shall be deleted in its entirety, it being understood that
under the Nokia PPA, if any payment is overdue, the Company simply accrues interest with no specific date of payment.”

 

     

     

    

 

1.07.  Additional
Covenants New Sections 6.16 and Section 6.17 shall be added to the Agreement as follows:

 

“6.16  Consulting
Agreement. On or before December 24_, 2015, the Company shall enter into an arrangement with *** (“***”) in form
and substance acceptable to the Collateral Agent that provides for *** to work with the Company to analyze the Patents in light
of potentially infringing products as part of the *** Consulting Agreement, and shall thereafter comply with the terms of
such arrangement and shall use its best efforts to implement and execute on a monetization plan consistent with ***’s and
Inventergy’s analysis.

 

6.17  Marketing
Patent Portfolio. Commencing on December 1, 2015, the Company shall diligently pursue and attempt to complete a sale of some
or all of the Patents, it being acknowledged and agreed that the consent of the Purchasers will be required to effect any such
transaction (other than a transaction that results in the payment in full of the Note Obligations and the satisfaction of the maximum
amount that the Purchasers could be entitled to under the Revenue Stream at that time). As part of this sale process, on or before
December 24, 2015, the Company shall enter into an arrangement with *** in form and substance satisfactory to the Collateral Agent
pursuant to which HTS will pursue a sale of some or all the Patents (the “*** Broker Agreement”), and shall
thereafter fully comply with the *** Broker Agreement. The Company shall, and shall direct *** to, keep the Collateral Agent fully
informed as to the Company and ***’s progress in marketing the Patents being offered for sale.“

 

1.08.  Events
of Default. Section 7.1.2(x) shall be amended by replacing the phrase “or 6.15” with “, 6.15, 6.16
or 6.17”

 

1.09.  Cumulative
Remedies. Section 7.2.4 shall be amended by replacing the parenthetical in clause (1)
with the following: 

 

“(to permit the Company’s continuing sublicense
to third parties to the extent required under the Existing Encumbrances and under any other licenses entered into in compliance
with this Agreement prior to such exercise of remedies, including in compliance with Section 7.2.3)” 

 

Section
2.  Advances to ***. The Company hereby authorizes and directs the Collateral Agent to release to ***
from the Collateral Account, from amounts that would otherwise be required to be applied to the Note Obligations or the Revenue
Stream, up to $200,000 to pay fees owed by the Company under the *** Consulting Agreement or to pay the actual fees or expenses
owed by the Company to brokers or other professionals in connection with the pursuit of a sale of all or a portion of the Patent
portfolio. Such advances shall be made at the Collateral Agent’s discretion at any time and from time to time after the date
hereof, shall be deemed made at the request of, and on behalf of, the Company, and shall not reduce the Company’s remaining
obligations to the Purchasers hereunder.

 

     

     

    

 

Section
3.  Effectiveness.

 

The effectiveness of this
2nd Amendment is subject to:

 

1.     the
receipt by the Collateral Agent of the following: (i) fully executed copies of this 2nd
Amendment, the *** Broker Agreement and the *** Consulting Agreement, and (ii) an officer’s certificate from an Authorized
Officer of the Company certifying that the representations and warranties of the Company contained in this Agreement are true and
correct as of the date hereof in all material respects, and that there exists no Default or Event of Default, after giving effect
to this 2nd Amendment; and

 

2.     the
Company’s payment of all fees and expenses (including attorneys’ fees) to the extent invoiced on or before the date
hereof (including, without limitation, reasonable fees and disbursements of Ropes & Gray LLP) incurred by the Collateral Agent
in connection with the preparation, negotiation, execution and delivery of this 2nd Amendment or otherwise owing under
the Agreement; provided, that the Company agrees to promptly pay any additional such amounts invoiced following the effectiveness
of the 2nd Amendment.

 

Section
4.  Miscellaneous. Except as specifically amended or waived above, the Agreement and the other Documents
shall remain unchanged and in full force and effect and are hereby ratified and confirmed. The execution, delivery and effectiveness
of this 2nd Amendment shall not operate as a waiver of any right, power or remedy of the Collateral Agent or any Purchaser
under the Agreement or any Document, nor constitute a waiver of any provision of the Agreement or any Document, except as specifically
provided by this 2nd Amendment. This 2nd Amendment is a Document, and a part of the Agreement, for all purposes
of the Agreement. This 2nd Amendment may be executed in any number of counterparts, and by different parties hereto
on separate counterpart signature pages, and all such counterparts taken together shall be deemed to constitute one and the same
instrument. Delivery of a counterpart signature page by facsimile transmission or by e-mail transmission of an Adobe portable document
format file (also known as a “PDF” file) shall be effective as delivery of a manually executed counterpart signature
page. Section headings used in this 2nd Amendment are for reference only and shall not affect the construction of this
2nd Amendment.

 

     

     

    

 

IN WITNESS WHEREOF, the
parties hereto have caused this 2nd Amendment to be duly executed and delivered as of the day and year first above written.

 

 

	 	Revenue Participant:
	 	 
	 	CF DB EZ LLC
	 	 
	 	 
	 	By:
	 	Title:

 

	 	Note Purchaser:
	 	 
	 	Drawbridge Special Opportunities Fund LP
	 	By: Drawbridge Special Opportunities GP LLC, its general partner

 

	 	 
	 	By:
	 	Title:
	 	 
	 	Collateral Agent:
	 	 
	 	DBD Credit Funding LLC
	 	 
	 	 
	 	By:
	 	Title:

 

[Signature Page to Second Amendment]

 

 

     

     

    

 

	 	Company:
	 	 
	 	INVENTERGY GLOBAL, INC.
	 	 
	 	By:     Joseph W. Beyers
	 	Title: Chief Executive Officer and Chairman
	 	 
	 	 
	 	INVENTERGY, INC.
	 	 
	 	 
	 	By:     Joseph W. Beyers
	 	Title: Chief Executive Officer and Chairman

 

[Signature Page to Second Amendment]Exhibit 10.27

 

CONFIDENTIAL

 

AMENDMENT TO PATENT PURCHASE AGREEMENT

 

This AMENDMENT is made
as of December 31, 2015 (“Amendment Date”) to that certain PATENT PURCHASE AGREEMENT (hereinafter referred to
as “Agreement”) entered into and effective as of October 21, 2013 (hereinafter referred to as “Effective
Date”), by and between Panasonic Corporation, a Japanese corporation having a principal place of business at 1006 Oaza
Kadoma, Kadoma-shi, Osaka 571-8501, Japan (hereinafter referred to as “Seller”) and Inventergy, Inc., a Delaware
corporation with a business address at 900 E. Hamilton Avenue, Suite 180, California 95008, USA (hereinafter referred to as “Buyer”).
Hereinafter, Seller and Buyer are each referred to as a “Party”, and collectively as the “Parties”.
All other definitions throughout this Amendment shall have the same definitions as in the Agreement, except as otherwise set forth.

 

RECITALS

 

WHEREAS, the
Parties entered into the Agreement to assign and transfer from Seller to Buyer Seller’s right, title and interest in and
to the Patent Assets; and

 

WHEREAS, Parties
wish to modify the terms of the payments from the Buyer to the Seller; and

 

WHEREAS, Parties
wish to clarify their intent as expressed in the Agreement;

 

NOW THEREFORE,
in consideration of the foregoing and of the mutual promises, covenants and agreements contained in the Agreement and this Amendment,
the Parties hereby agree as follows:

 

Definitions Section 1:

 

Definitions (m) “Guaranteed Payments”
and (n) “Guaranteed Payment Dates” are deleted in their entirety.

 

Definition (l) “Gross Revenue”
is amended and restated in its entirety as follows:

 

(l) “Gross
Revenue” shall mean total income and revenue and any non-cash equivalents obtained by Buyer in relation to Buyer’s
commercialization activities for Patent Assets, including but not limited to the licensing, selling or other monetization of any
of the Patent Assets. If Inventergy offsets any amount of royalties that it would otherwise obtain from an entity as a result of
commercialization of the Patent Assets against any debt that it owes to the same entity, such offset should be included as Gross
Revenue.

 

    	 	1	 

     

    

 

CONFIDENTIAL

 

Definition (q) “Net Revenue”
is amended and restated in its entirety as follows:

(q) “Net Revenue” shall
mean all proceeds, income, payments and revenues obtained (actually received as cash) by Buyer during the term of this Agreement
and/or after its termination in relation to Buyer’s commercialization activities for Patent Assets, including but not limited
to the licensing, selling, or other monetization of any of the Patent Assets, after deducting from Gross Revenue: (1) any governmental
taxes including withholding taxes, (2) any reimbursement to its licensees due to overpayments from such licensees to Buyer; and
(3) any and all accrued litigation and/or patent monetization commercialization-related third party invoiced expenses (preparation,
execution or contingency fee payments) (hereinafter, such deducted costs shall be referred to as “Deducted Costs”).
Provided, however, that after the Amendment Date, Deducted Costs shall not include any external or internal patent prosecution
costs, including but not limited to legal fees or translation fees for patent prosecution related matters, or patent maintenance
costs. In any event, the accrued Deducted Costs deducted from Gross Revenue to yield a particular quarterly Net Revenue shall not
exceed more than fifty percent (50%) of the Gross Revenue applicable to that particular quarterly Net Revenue, but any excess accrued
Deducted Costs may be applied to subsequent Net Revenue. For the avoidance of doubt, Buyer is solely liable for any third party
litigation related costs and negotiation related costs. None of Buyer’s internal costs of operation, including but not limited
to any costs associated with the commercialization of the Patent Assets and Buyer’s internal costs associated with litigation
in support of commercialization efforts, shall be deducted in Net Revenue calculations. For the avoidance of doubt, Net Revenue
does not encompass any receipts by Buyer due to general corporate financing, whether equity or debt, or money or other value received
as part of changes of control, mergers or acquisitions of substantially all the assets of Buyer, its successor or assigns, or similar
general corporate transactions. Notwithstanding anything to the contrary, from the Amendment Date until such time as Seller has
received an aggregate of eighteen (18) million US Dollars in Net Revenue Share (the “Milestone Payment”), the
deduction of any Deducted Costs from Gross Revenue shall be deferred to later Gross Revenue, and the costs deducted from Gross
Revenue during such time shall be zero.

 

    	 	2	 

     

    

 

CONFIDENTIAL

 

Section 2.5
“Grant Back” the following is added at the end of Section 2.5 to further clarify the intent of the Parties as of the
Effective Date: “For purposes of clarity, Buyer and Seller understand, acknowledge and agree that any reference to buyer’s
or acquirer’s products and services in this Section 2.5 is limited to products and services that such party acquires as part
of Seller’s sold business.”

 

Section 3.4
“Guaranteed Payments” is deleted in its entirety

 

Section 3.5 “Taxes” is amended
to delete “Guaranteed Payments” in each occasion therein.

 

Section 3.6 “Failure of Payment”
is amended to delete the words “and/or 3.4” and the words “and/or Guaranteed Payment Date,”

 

Sections 4.2 “Termination and Re-Purchase
of Patent Assets” is amended and restated in its entirety as follows:

 

Re-Purchase of Patent Assets. If
Buyer ceases to be a public company with securities listed on NASDAQ, another stock exchange or any over-the-counter quotation
service, Buyer shall notify Seller of such change at least 60 days prior to such change becoming effective. Prior to ten (10) days
before any such change becomes effective, upon notice to Buyer, Seller shall then have the right to re-purchase the Patent Assets
for reasonable consideration (subject to the rights that Buyer has already granted to any Settled Third Party). In no event shall
the reasonable price for re-purchasing the Patent Assets be lower than the lesser of (i) eight (8) million US Dollars, or (ii)
the total accrued payments of Up-front Payment and Net Revenue Share paid by Buyer up to the date when Seller exercised the option
set forth in this Section 4.2. Seller shall be responsible for any costs related to the transfer of the Patent Assets. Further,
if Buyer’s total accrued payments of Up-front Payment and Net Revenue Share payments paid to Seller exceeds twenty-three
(23) million US Dollars, Seller has no further option to re-purchase the Patent Assets.

 

Section 4.3 “Effect of Termination”
is amended and restated in its entirety as follows

 

Effect of Re-Purchase of Patent Assets.

 

(a)          If
Seller exercises its option to re-purchase the Patent Assets under Section 4.2 hereof, Seller will grant Buyer a limited right
to sublicense to any third party that has already settled or agreed to settle with Buyer for a license to the Patent Assets on
or before the termination date (hereinafter, such third party shall be referred to as a “Settled Third Party”),
and Buyer shall pay to Seller any amount of Net Revenue Share (including the future Net Revenue Share which will be obtained after
the termination date) for amounts which Buyer had settled or agreed with, and received from, such Settled Third Party.

 

    	 	3	 

     

    

 

CONFIDENTIAL

 

(b)          Within
sixty (60) days after the date of re-purchase, Buyer shall render a report and pay all accrued amounts owing under Section 3 of
this Agreement to Seller. For the avoidance of doubt, Buyer shall continue to pay to Seller any amount of Net Revenue Share (including
the future Net Revenue Share which will be obtained after the termination date) which Buyer has settled or agreed with any Settled
Third Party with respect to Buyer’s commercialization activities on or before the termination date of this Agreement.

 

(c)          Seller
shall retain the right to conduct an audit in accordance with Section 3.8 hereof after Seller re-purchases the Patent Assets, and
Buyer shall retain books and records as required until after such audit and any subsequent dispute arising from such audit.

 

Section 8.2 “Fees and Other Actions”,
the following is added at the end of 8.2(b):

 

Prior to ten (10) days before the final
deadline for the payment of any maintenance or other fee, or the submission of any office action or other communication to any
patent office that would have the effect of abandonment (except for patents or patent applications abandoned in favor of one or
more continuation, continuation-in-part, divisional, reissue, reexamination or other equivalent application or patent; or patent
applications abandoned in response to one or more rejections or equivalent by an examining patent office), upon notice to Buyer,
Seller shall then have the right to cause Buyer to assign any such Patent Assets to Seller and to grant back to Seller all rights,
title and interest in such Patent Assets without monetary consideration. Seller shall be responsible for any costs related to the
transfer of the Patent Assets.

 

Section 9.3 “Notices” is restated
in its entirety as follows:

 

		9.3	Notices. All notices under this Agreement shall
be in writing, specifically refer to this Agreement, and be delivered in person or sent by international carrier or overnight
mail, or by other means providing proof of delivery, to the Parties at their respective addresses set forth below, or to any other
address of which a Party notifies the other. Other communications under this Agreement may be made by any of the foregoing means
as well as electronic mail to an e-mail address designated by a Party. All notices shall be deemed to be effective on the date
of actual receipt or five days after transmission as provided above, whichever is sooner.

 

    	 	4	 

     

    

 

CONFIDENTIAL

 

	IF TO SELLER:	IF TO BUYER:
	
        Panasonic Corporation

        Intellectual Property Center
	
        Inventergy, Inc.

        900 E. Hamilton Avenue

	2-1-61 Shiromi, Chuo-ku, Osaka City	Suite 180
	540-6208, Japan	Campbell, CA 95008, USA
	
        Attention:

        General Manager, Licensing Group
	
        Attention: Joe Beyers

        Chairman & CEO

	Email:katsura.hitoshi@jp.panasonic.com	Email: joe@inventergy.com

 

[The remainder of this page has been
intentionally left blank. Signature page follows.]

 

    	 	5	 

     

    

 

CONFIDENTIAL

 

IN WITNESS WHEREOF,
the Parties have caused this Amendment to be executed in duplicate by its duly authorized representative.

 

	 	Panasonic Corporation	 	 	Inventergy, Inc.
	 	 	 	 	 
	By:	 	 	By:	 
	 	(Signature)	 	 	(Signature)
	 	 	 	 	 
	Name:	Hideo
    Toyoda	 	Name:	Joseph
    W. Beyers
	 	 	 	 	 
	Title:	Director, Intellectual
    Property Center	 	Title:	Chariman & CEO
	 	 	 	 	 
	Date:	 	 	Date:	 

 

    	 	6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00256-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00256-of-00352.parquet"}]]